Last reviewed · How we verify
MCC-based 13% drug loaded tablets — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
MCC-based 13% drug loaded tablets (MCC-based 13% drug loaded tablets) — AstraZeneca.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| MCC-based 13% drug loaded tablets TARGET | MCC-based 13% drug loaded tablets | AstraZeneca | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- MCC-based 13% drug loaded tablets CI watch — RSS
- MCC-based 13% drug loaded tablets CI watch — Atom
- MCC-based 13% drug loaded tablets CI watch — JSON
- MCC-based 13% drug loaded tablets alone — RSS
Cite this brief
Drug Landscape (2026). MCC-based 13% drug loaded tablets — Competitive Intelligence Brief. https://druglandscape.com/ci/mcc-based-13-drug-loaded-tablets. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab